N/A N=36 Stereotactic Body Radiotherapy for Spine Tumors
Spinal Metastases · Vertebral Metastases · Benign Spinal Tumors
Primary: Initial Symptom Control — 3; 28; 3; 27 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=21 Stereotactic Body Radiation Therapy (SBRT) for Tumors Near the Spinal Cord
Spinal Tumors
Primary: Toxicity — 14; 0; 0; 0 participants
N/A N=51 Spinery® A Novel Radio-Frequency Tumor Ablation Device for Spine Metastatic Tumors
Vertebral Metastasis
Primary: Change From Baseline in Worst Pain and Quality of Life Scores at 3 Months Using the Brief Pain Inventory (BPI) and EQ-5D-5L Questionnaires — 3.4; 65.2 points on a…
N/A N=30 Image-guided Cryoablation of Head, Neck and Spine Tumors
Head and Neck Neoplasms · Malignant Neoplasm of Vertebral Column
Primary: Number of Participants Undergoing Image-guided Cryoablation of a Head, Neck, or Spine Tumor With Adverse Events — 3; 0 participants
Phase 2 N=33 Radiotherapy for Solid Tumor Spine Metastases
Solid Tumor Spine Metastases
Primary: Number of Participants With Radiographic Recurrence at 12 Months — 3 Participants
Phase 3 N=16 Randomized Study Comparing Local Tumor Control After Post-Operative Single-Fraction or Hypofractionated Stereotactic Radiosurgery in the Treatment of Spinal Metastases
Spinal Metastases
Primary: Local Tumor Control Using MRI or CT
Phase 3 N=46 Image-Guided Radiosurgery or Stereotactic Body Radiation Therapy in Treating Patients With Localized Spine Metastasis
Metastatic Cancer · Pain
Primary: Percentage of Patients Receiving Radiosurgery/SBRT Per Protocol or With Minor Variation (Phase II) — 39; 37 Participants
Phase 2 N=35 Stereotactic Body Radiation Therapy and Vertebroplasty in Treating Patients With Localized Spinal Metastasis
Metastatic Cancer · Pain · Unspecified Adult Solid Tumor, Protocol Specific
Primary: Pain Response as Measured by VAS at 3 Months — 8; 12; 1 Participants
Phase 2 N=71 Evaluation of Single Session Stereotactic Body Radiotherapy
Spinal Neoplasms
Primary: Complete Pain Relief Using Stereotactic Body Radiotherapy (SBRT) to Treat Spine and Para- Spinal Tumors in a Single Session — 18 Participants
N/A N=24 Adaptive Staged Stereotactic Body Radiation Therapy in Treating Patients With Spinal Metastases That Cannot Be Removed by Surgery
Melanoma · Metastatic Malignant Neoplasm in the Spine · Renal Cell Carcinoma
Primary: Distance Between the Gross Disease and Spinal Cord (Cord-disease Distance, CDD) of at Least 3mm After Treatment. — 1; 14 Participants
N/A N=44 High-precision Radiotherapy of Motor Deficits Due to Metastatic Spinal Cord Compression
Spinal Cord Compression Due to Metastasis to Spine
Primary: Number of Participants Who Were Alive at 6 Months After Radiotherapy Without Deterioration of Motor Function During (or Directly After) Radiotherapy and Freedom From…
N/A N=203 Radiotherapy of Motor Deficits From Metastatic Epidural Spinal Cord Compression
Metastatic Epidural Spinal Cord Compression
Primary: Number of Participants Showing Improvement or no Further Progression of Motor Deficits at 1 Month Following Radiotherapy — 68; 69 Participants
N/A N=43 A Phase II Study of Spinal Radiosurgery
Neoplasm · Arteriovenous Malformations
Primary: Number of Participants With Palliative Response (Pain or Relief of Neurologic Symptoms) From Single Fraction Radiosurgery Delivered With Tomotherapy — 29 Participants
N/A N=41 A Prospective Study Using Implanted Fiducial Markers to Assess Treatment Accuracy and Esophageal Toxicity in Spinal Stereotactic Body Radiation Therapy
Spinal Tumor
Primary: Overall Response at Protocol Treatment Site — 23; 2; 7; 0 Participants
N/A N=38 An Investigational Scan (7T MRI) for the Imaging of Central Nervous System Tumors
Central Nervous System Neoplasm · Glioma · Metastatic Malignant Neoplasm in the Central Nervous System
Primary: Contrast-to-noise Ratio (CNR) — 60.6; 58.4 contrast-to-noise ratio
N/A N=229 Study Comparing Stereotactic Body Radiotherapy vs Conventional Palliative Radiotherapy (CRT) for Spinal Metastases
Spinal Metastases
Primary: Phase III: Complete Pain Response at 3 Months Post-radiation — 16; 40; 29; 20 Participants — p=0.0002
N/A N=3 Spinal Cord Stimulation in Spinal Muscular Atrophy
Spinal Muscular Atrophy Type 3 · Spinal Muscular Atrophy Type 4
Primary: Muscle Weakness — 2; 3 Participants
N/A N=10 Pilot Study of Same-session MR-only Simulation and Treatment With Stereotactic MRI-guided Adaptive Radiotherapy (SMART) for Oligometastases of the Spine
Oligometastases of the Spine
Primary: Number of Participants to Receive Delivery of the First Fraction of Same-session MRI-only Simulation and Treatment With SMART on the First On-table Attempt — 8…
N/A N=75 Transesophageal Echocardiography (TEE): A Novel Technique for Spinal Cord Imaging
Spinal Cord · Epidural
Primary: Number of Thoracic Spinal Segments Successfully Visualized With TEE — 12; 10 Thoracic segments
N/A N=58 Functional Monitoring for Motor Pathway in Brain Tumor Surgery Within Eloquent Area
Glioma, Motor Pathway
Primary: Extent of Tumor Resection — 40; 7; 7; 4 participants
N/A N=100 Sagittal Plane Shear Index for Planning Lumbar Stenosis Surgery
Lumbar Spinal Stenosis · Spondylolisthesis
Primary: Proportion of Surgical Plans Recorded Prior to the SPSI Report That Are Altered After Integration of SPSI Into the Surgical Planning — 47; 22; 6 Surgical plans
N/A N=3 Image-Guided Navigation for High Dose Rate Temporary Interstitial Brachytherapy in the Palliative Management of Previously Treated Tumors of the Spine and Pelvis
Metastatic or Recurrent Lesions in the Spine · Metastatic or Recurrent Lesions in the Pelvis
Primary: Maximum Radiation Dose — 7 cord/cauda max dose in Gy
N/A N=18 Spinal Cord Stimulation to Augment Activity Based Therapy
Transcutaneous Spinal Stimulation · Walking · Spasticity
Primary: Change in Walking Function - 10m Walk Walking Speed (m/s) — 0.06; 0.16 speed difference in meters per second
N/A N=158 Study to Evaluate Safety and Effectiveness of Spinal Sealant
Spinal Procedure Requiring Dura Incision
Primary: Watertight Dural Closure — 102; 36 Participants
N/A N=33 Prospective, Multicenter da Vinci® SP™ Surgical System TORS Study
Oropharyngeal Cancer
Primary: Performance — 0 Participants
Phase 4 N=27 Intrathecal (IT) Baclofen Drug Distribution
Muscle Spasticity
Primary: Subjects Experiencing Maximal MAS Change From Baseline - Spasticity of Cerebral Origin — 8; 7; 3; 3 Participants
Phase 2 N=8 Combination of Hydroxyurea and Verapamil for Refractory Meningiomas
Cancer · Brain Cancer · Meningioma
Primary: Number of Participants Experiencing Serious Adverse Events Including But Not Limited to Hospitalizations, Deaths Related to Treatment, or Other Incapacitating…
Phase 2 N=15 Thalidomide and Temozolomide in Relapsed or Progressive CNS Disease or Neuroblastoma
Central Nervous System Tumor, Pediatric · Neuroblastoma
Primary: Therapy Completion Rate — .40 proportion of participants
Phase 4 N=304 Spinal Cord Stimulation for Low Back Pain
Chronic Pain
Primary: Effectiveness of SCS Stimulation in Reducing Back Pain Associated With Failed Back Surgery Syndrome After 12 Months of Use.
N/A N=710 INFUSE® Bone Graft/ PEEK Interbody Spacer/ Anterior Cervical Plate Pivotal Clinical Trial
Degenerative Disc Disease
Primary: Rate of Overall Success — 80.9; 59.9 percentage of participants — p=<0.001